You are here

Vaccine in CML- Abstract AACRJournals

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2St. Agnes Hospital, Baltimore, Maryland; 3Medical University of South Carolina, Charleston, South Carolina; and 4Cell Genesis, South San Francisco, California
Corresponding Author:
B. Douglas Smith, Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 246 CRB1, Baltimore, MD 21231. Phone: 410-614-5068; Fax: 410-614-7437; E-mail: bdsmith@jhmi.edu.

Abstract

Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia.

full abstract:
http://clincancerres.aacrjournals.org/content/16/1/338.abstract